Navigation Links
Both Biosimilar and Reference Biologics Companies Must consider Various Product-Specific and Regional Strategies to Navigate a Dynamic and Uncertain Global Market
Date:4/8/2013

EXTON, Pa., April 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, with sales forecasted to exceed $16.8 billion by 2021, manufacturers competing in the biosimilars market must adopt clear and effective strategies early in product development to maximize potential commercial return. According to Biosimilars Advisory Service: Corporate Strategies, after identifying an optimal biologic target and determining partnerships, biosimilar sponsors need to balance clinical development burdens with sales and marketing strategies and the option of pursuing interchangeability status in the United States in order to compete successfully.

The 2013 Biosimilars Advisory Service report finds that, despite a continued increase of branded biologics sales through 2014, the entrance of commercially relevant, lower-cost biosimilars and resultant brand price cuts will cause the overall biologics market to decrease over the second half of the forecast period across the seven major pharmaceutical markets.

"Innovator companies stand to lose considerable revenue from their key biologic drugs as a result of biosimilar erosion, especially those that rely heavily on biologic sales with near-term patent expiries," said Andrew Merron , Ph.D., Senior Director, Biosimilars Research at Decision Resources Group. "It's imperative for these companies and biosimilars manufacturers to adopt product-based and regional strategies individualized by their respective challenges and opportunities."

Based on analysis of surveys from over 600 key industry stakeholders and extensive secondary market research, report findings reveal that branded biologics companies should implement unique, product-specific strategies focusing on the development of biobetters, a reliable legal defense, alternative pricing tactics and potential counter-detailing messages to combat biosimilar competition.

The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.Bio-Trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:BioTrends Research Group Decision Resources GroupAllison Thrower

Liz Marshall781-993-2604

781-993-2563athrower@dresourcesgroup.com

emarshall@dresourcesgroup.com 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
2. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
3. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
4. ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming; Urges Distinct Naming Requirement
5. Reliance Pharmaceuticals: Biosimilars Company Analysis
6. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
7. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
8. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
9. Musculoskeletal Network Launches Special Coverage of FDA Biosimilars Policy
10. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
11. Global Biosimilars: A return to optimism?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2020)... ... February 10, 2020 , ... Aspire Regenerative, a ... to patients. , EMSculpt is an FDA-approved treatment designed to burn fat ... thighs, calves, biceps, and triceps. The EMSculpt machine utilizes HIFEM® (High-Intensity Focused Electromagnetic) ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... ... A. James, MS, RDN, has been selected as the chief of Nutrition and ... for all food service operations and clinical nutrition programs for the health care ...
(Date:2/10/2020)... ... 2020 , ... SentryHealth announced today the expansion ... clinics. Focused on leading innovation in the treatment of chronic disease, Healthstat will ... employee health clinics. Healthward delivers greater insight into eligibility for chronic care management ...
Breaking Medicine Technology:
(Date:2/10/2020)... ... February 10, 2020 , ... Buxton is ... company’s healthcare division. In this role, Nikki will support Buxton’s current and prospective ... healthcare product development. , “The healthcare industry is increasingly understanding the importance ...
(Date:2/10/2020)... , ... February 10, 2020 , ... ... has received 510(k) clearance for use with the Legacy™ and InterActive™ systems and ... combine ideal esthetics for your patients and more freedom of choice for your ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... ... management of chronic cardiometabolic conditions across populations, today announced its founder and chief ... HIMSS’ Most Influential Women in Health IT . Established in 2016, the ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... Real ... and the company that started a real food revolution in the medical community, is ... an extraordinary member of the feeding tube community each year during Feeding Tube ...
(Date:2/9/2020)... (PRWEB) , ... February 08, 2020 , ... Dr. Ezzat ... Dr. Nina Minagawa sent out a message to her professional network calling for support ... call. Both Moghazy and now RYM Director Dr. Minagawa have both been instrumental in ...
Breaking Medicine News(10 mins):